Inhibitor Therapeutics INTI Income Statement (2012-2026)

OTC INTI
$0.07 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

Inhibitor Therapeutics Quarterly Income Statement

Periods 55 quarters
Latest Jun 2026

Inhibitor Therapeutics reported net income of -$0.61M for the quarter ended Jun 2026. This income statement covers 55 quarters of results from Dec 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
375.88M376.86M376.86M376.86M376.86M366.18M171.79M171.97M172.02M172.02M172.32M172.32M172.32M172.32M172.32M172.57M172.57M172.57M172.57M173.79M
Operating items
Research & DevelopmentR&D
75.000.01M0.20M0.23M0.26M0.68M0.26M0.24M0.37M0.89M0.24M0.33M0.38M0.76M0.34M0.22M
Selling, General & AdministrativeSG&A
0.07M0.03M0.09M0.06M0.07M0.42M0.43M0.51M0.50M0.59M0.51M0.35M0.44M0.60M0.44M0.37M0.36M0.56M0.36M0.40M
Other Operating ExpensesOther Opex
Operating ExpensesOpex
0.07M0.03M0.09M0.07M0.07M0.42M0.63M0.74M0.76M1.27M0.77M0.59M0.81M1.48M0.67M0.70M0.74M1.32M0.70M0.62M
Operating IncomeOp. Inc
-0.07M-0.03M-0.09M-0.07M-0.07M-0.42M-0.63M-0.74M-0.76M-1.27M-0.77M-0.59M-0.81M-1.48M-0.67M-0.70M-0.74M-1.32M-0.70M-0.62M
EBIT
-0.07M-0.03M-0.09M-0.07M-0.07M-0.42M-0.63M-0.74M-0.76M-1.27M-0.77M-0.59M-0.81M-1.48M-0.67M-0.70M-0.74M-1.32M-0.70M-0.62M
Non-operating items
Non Operating Interest Expenses
0.00M0.00M0.01M0.01M0.01M0.00M
Interest & Investment IncomeInt & Inv Inc
0.09M0.09M0.09M0.11M0.09M0.08M0.08M0.06M0.04M0.04M0.03M0.02M0.01M0.00M
Other Non Operating IncomeOther Non Op Inc.
Net income details
EBT
-0.07M-0.03M-0.10M-0.08M-0.08M-0.43M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Tax ProvisionsTaxes
Profit After TaxPAT
-0.12M0.12M-0.10M-0.08M-0.08M12.36M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Income from Non-Controlling InterestsInc. Minority
Income from Continuing OperationsIncome (Continuing)
-0.07M-0.03M-0.10M-0.08M-0.08M-0.43M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Consolidated Net IncomeConsol Net Inc.
-0.07M-0.03M-0.10M-0.08M-0.08M-0.43M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Income towards Parent CompanyParent Net Inc
-0.12M-0.08M-0.15M-0.13M-0.13M-0.43M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Preferred Dividend PaymentsPref Dividends
0.05M0.05M0.05M0.05M0.05M0.04M
Net Income towards Common StockholdersNet Income
-0.12M-0.08M-0.15M-0.13M-0.13M12.32M-0.54M-0.65M-0.66M-1.17M-0.68M-0.50M-0.73M-1.42M-0.63M-0.66M-0.71M-1.30M-0.69M-0.61M
Additional items
EPS (Basic)
0.000.000.000.000.000.030.000.000.00-0.010.000.000.00-0.010.000.000.00-0.010.000.00
EPS (Diluted)
0.000.000.000.000.000.030.000.000.00-0.010.000.000.00-0.010.000.000.00-0.010.000.00
Shares Outstanding
376.71M376.25M376.86M376.86M376.86M366.18M171.79M171.97M172.01M171.95M172.08M172.32M172.32M172.26M172.32M172.57M172.57M172.51M172.57M173.31M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
376.71M376.25M376.25M376.86M376.86M367.78M171.79M171.97M172.01M171.95M172.08M172.32M172.32M172.26M172.32M172.57M172.57M172.51M172.57M173.31M
EBITDA
-0.07M-0.03M-0.09M-0.07M-0.07M-0.42M-0.63M-0.74M-0.76M-1.27M-0.77M-0.59M-0.81M-1.48M-0.67M-0.70M-0.74M-1.32M-0.70M-0.62M
Interest ExpensesInt Expense
0.00M0.00M0.01M0.01M0.01M0.00M
Tax Rate